Vivos Therapeutics Inc (VVOS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.19+6.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Improve operating income and cash flow: metric not reported.
Vivos grew revenue 70% in Q1 2026. It aims to keep growing sales. The company works on cost savings but has losses. It raised money to support growth.
Vivos lost more money recently. It risks Nasdaq delisting. Sales growth may slow. The company needs more cash and faces big risks.
The market expects about 47% revenue growth. Our fair value is $3.74. The stock price reflects high risk and losses.
Breaks if: Fails to raise capital needed to continue operations
Raise capital through equity offerings and manage financing to support operations and growth initiatives.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds to the uncertainty of its long-term performance.
The market seems to have priced in a low level of fragility, reflecting a justified valuation compared to peers. However, the expectations are tempered by the company's recent financial performance, which has not kept pace with its industry cohort.
Management is focused on expanding sleep testing capacity and strategic partnerships, which have shown some progress. However, the company remains at risk of missing earnings expectations, particularly given its history of recent misses and a high miss probability.
The long-term thesis hinges on whether VVOS can maintain its growth trajectory through successful capacity expansion and partnerships. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping its future.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company announced a new facility in Henderson, Nevada. This facility is expected to more than double production capacity to over $10 million. The CEO stated that referrals in the Las Vegas market have more than doubled. This suggests higher demand in that area. However, the company also missed revenue forecasts in Q2. This revenue shortfall raises concerns about future growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 disclosures including 2026-Q1 and 2026-Q2. Cash was $2.0 million at end 2025, increased by $6.8 million in financing proceeds. Management announced a proposed rights offering in mid-2026 to raise capital. Operating loss widened to $19.9 million in 2025 from $11.2 million in 2024. The trajectory shows active capital raising efforts to support operations amid ongoing losses.
“Entered into material definitive agreements including PIPE SPA with investors for capital raising.”
“Management highlighted strengthened capital structure positioning Vivos to drive growth.”
Breaks if: Operating losses worsen beyond -$6.6M next year
Breaks if: Stock price falls below Nasdaq minimum bid price
Breaks if: YoY revenue growth falls below 46.5% in FY26
Focus on increasing top-line revenue through acquisitions, collaborations, and expanded service offerings in sleep disorder treatment.
In the next 1 to 3 years, VVOS faces significant challenges but also opportunities for growth if management can execute effectively. Not investment advice.